ARTICLE | Clinical News

IFX-1: Ph II started

January 6, 2017 10:04 PM UTC

InflaRx began an open-label, Greek Phase II trial to evaluate once-weekly IV IFX-1 for 8 weeks in 12 patients who have failed previous antibiotic or biological treatment....

BCIQ Company Profiles

InflaRx N.V.

BCIQ Target Profiles

Complement 5a (C5a)